Engagement models
One partnership. End-to-end discovery.
One multidisciplinary team stays with your program from design through molecule delivery. The business terms flex to fit the program.
How we work together.
Every program is built around the outcome you need. You work 1:1 with the scientists doing the work, with a named program lead and regular data reviews from kickoff to delivery.
One partnership.
End-to-end discovery.
- Deep experience: 35 years of antibody discovery across pharma, biotech, and academia.
- Clinical track record: 20+ publicly disclosed client antibodies have advanced from our lab into clinical development. Publicly disclosed programs only; additional client antibodies have advanced under partner confidentiality.
- Science and technology together: advanced wet lab workflows with LensAI™ analysis inside them.
- Stronger starts: risks surfaced early, giving programs greater chances of success.
- Faster progress: reproducible workflows that support evidence-driven advancement.
- Make all data useful: patented HYFT® technology integrates new and existing data to generate novel biological evidence.
20+ publicly disclosed client antibodies have advanced from our lab into clinical development. Publicly disclosed programs only; additional client antibodies have advanced under partner confidentiality.
>98% discovery success with leading B cell technology *
*“Success” refers to meeting predefined discovery criteria, not clinical or therapeutic outcomes. Results may vary.
An established partner to pharma and technology innovators
Leadership perspective
“We unite science and technology to bring new power to discovery. Partnership with MindWalk comes at a pivotal moment for our industry, where the complexity of biology and the scale of data demand new approaches. Together, we expand what’s possible, helping advance discovery with greater insight, connectivity, and continuity.”
Jennifer Bath, PhD
CEO, MindWalk